{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:39:23Z","timestamp":1787593163100,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>In Australia, oxycodone has been associated with increasing rates of harm over time, despite reduced use, reformulation to a tamper\u2010resistant form and in contrast to most prescription opioids. We explored characteristics of oxycodone\u2010related ambulance attendances to understand whether presentation characteristics could explain increasing oxycodone harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective study of coded ambulance patient care records related to extramedical oxycodone use, January 2013 to September 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Victoria, Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases<\/jats:title>\n                    <jats:p>A total of 2788 oxycodone\u2010related ambulance attendances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Primary outcomes were temporal changes in characteristics of oxycodone presentations over time (from 2013 to 2018) and following reformulation. Covariates include demographic characteristics, presentation severity, mental health, substance use and poisoning intent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Average age was 41.3 (\u00b1\u00a016.4) years with females comprising 56.4% of attendances (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02788). The proportion of females in oxycodone\u2010related attendances increased over time [an average increase in the odds ratios of 5% per year (OR)\u00a0=\u00a01.05, 95% confidence interval (CI)\u00a0=\u00a01.01\u20131.10]. Other temporal trends included a reduced likelihood of naloxone administration (OR\u00a0=\u00a00.92, 95% CI\u00a0=\u00a00.85\u20131.00), heroin involvement (OR\u00a0=\u00a00.81, 95% CI\u00a0=\u00a00.66\u20130.99), comorbid mental health symptoms (OR\u00a0=\u00a00.87, 95% CI\u00a0=\u00a00.82\u20130.92) and unknown intent poisoning (OR\u00a0=\u00a00.91, 95% CI\u00a0=\u00a00.85\u20130.96); and a greater risk of alcohol involvement (OR\u00a0=\u00a01.06, 95% CI\u00a0=\u00a01.01\u20131.11), non\u2010opioid extramedical pharmaceutical use (OR\u00a0=\u00a01.05, 95% CI\u00a0=\u00a01.01\u20131.10), comorbid suicidal thoughts or behaviours (OR\u00a0=\u00a01.10, 95% CI\u00a0=\u00a01.05\u20131.15) and past history of psychiatric issues (OR\u00a0=\u00a01.22, 95% CI\u00a0=\u00a01.16\u20131.27). Interrupted time\u2013series analysis showed that reformulation was associated with an immediate effect on sex, severity, accidental poisoning and unknown intent poisoning, although these were not sustained over time. Alcohol involvement in the attendance (OR\u00a0=\u00a01.43, 95% CI\u00a0=\u00a01.17\u20131.74, i.e. an average increase in the odds of 43% per year), Glasgow Coma Scale (OR = 1.28, 95%CI 1.04 \u2013 1.57), a previous history of psychiatric issues (OR\u00a0=\u00a00.80, 95% CI\u00a0=\u00a00.70\u20130.92, i.e. an average decrease in the odds of 20% per year, heroin involvement (OR = 0.22, 95% CI = 0.05 \u2013 0.98) and illicit drug use (OR = 0.45, 95% CI = 0.23 \u2013 0.87) showed statistically significant relative changes following the reformulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The characteristics of oxycodone presentations in Australian ambulances attendances appear to be changing over time, including more female presentations; increasing alcohol use, extramedical use of non\u2010opioid pharmaceuticals and suicidal thoughts or behaviours and decreasing heroin and illicit drug involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.15365","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T14:21:47Z","timestamp":1607610107000},"page":"2233-2241","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics of oxycodone\u2010related ambulance attendances: analysis of temporal trends and the effect of reformulation in Victoria, Australia from 2013 to 2018"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"first","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Scott","sequence":"additional","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"},{"name":"Turning Point Eastern Health and Eastern Health Clinical School, Monash University  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-7293","authenticated-orcid":false,"given":"Tina","family":"Lam","sequence":"additional","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smith","sequence":"additional","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"},{"name":"Department of Epidemiology and Preventive Medicine Monash University  Victoria Australia"},{"name":"Ambulance Victoria  Victoria Australia"},{"name":"Department of Community Emergency Health and Paramedic Practice  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-1937","authenticated-orcid":false,"given":"Dan I.","family":"Lubman","sequence":"additional","affiliation":[{"name":"Monash Adiction Research Centre, Eastern Health Clinical School  Victoria Australia"},{"name":"Turning Point Eastern Health and Eastern Health Clinical School, Monash University  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152e1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2019.0541"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3931"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4369"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.035"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090784"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14896"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7621"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228316"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.12.007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029170"},{"key":"e_1_2_8_14_1","unstructured":"Australian Bureau of Statistics.3101.0\u2014Australian Demographic Statistics March 2018. Available at:http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/3101.0(Accessed 06 December 2019)."},{"key":"e_1_2_8_15_1","volume-title":"2033.0.55.001\u2014Census of Population and Housing","author":"Australian Bureau of Statistics","year":"2018"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-2-8"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-6405.12568"},{"key":"e_1_2_8_18_1","volume-title":"Opioid harm in Australia and comparisons between Australia and Canada. Cat. no. HSE 210","author":"Australian Institute of Health and Welfare (AIHW)","year":"2018"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3767"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.10.002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.180646"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000337"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.05.010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2015.5222"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13118"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.11.025"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14784"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1801417"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1802148"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15365","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:16:40Z","timestamp":1787591800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/add.15365"],"URL":"https:\/\/doi.org\/10.1111\/add.15365","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"2020-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}